Evidence summaries for semaglutide across type 2 diabetes, obesity, cardiovascular outcomes, kidney outcomes, safety, dosing, and comparative therapy.
An echocardiography substudy of the STEP-HFpEF Program found once-weekly semaglutide 2.4 mg attenuated adverse cardiac remodeling versus placebo over 52 weeks. PICO summary and expert commentary.
A pooled secondary analysis of the STEP-HFpEF and STEP-HFpEF DM trials examined whether baseline atrial fibrillation modified the benefit of once-weekly semaglutide 2.4 mg in obesity-related HFpEF. PICO summary and expert commentary.
An echocardiography substudy of the STEP-HFpEF Program found that once-weekly semaglutide 2.4 mg attenuated adverse cardiac remodeling versus placebo over 52 weeks. PICO summary and expert commentary.
Prespecified FLOW secondary analysis testing whether semaglutide's kidney and cardiovascular benefit differs by baseline SGLT2 inhibitor use in type 2 diabetes with chronic kidney disease. PICO summary and expert commentary.
Pre-specified FLOW subgroup analysis of semaglutide for kidney outcomes in type 2 diabetes and chronic kidney disease, by baseline SGLT2 inhibitor use. PICO summary and expert commentary.
Pooled patient-reported outcomes from the STEP 1-4 trials show semaglutide 2.4 mg improved physical functioning versus placebo over 68 weeks. PICO summary and expert commentary.
A prespecified analysis of the SELECT randomised trial showing sustained four-year weight loss with semaglutide versus placebo in adults with cardiovascular disease and obesity but no diabetes. PICO summary and expert commentary.
Secondary analysis of the SELECT trial finds once-weekly semaglutide 2.4 mg modestly lowered a composite kidney endpoint versus placebo in adults with overweight or obesity and cardiovascular disease but no diabetes. PICO summary and expert commentary.
Prespecified pooled analysis of the STEP-HFpEF program: once-weekly semaglutide 2.4 mg improved NYHA functional class versus placebo in obesity-related HFpEF. PICO summary and expert commentary.
In the FLOW trial, once-weekly semaglutide 1.0 mg lowered the risk of major kidney disease events and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
